Articles On Adherium (ASX:ADR)

The S&P ASX 200 Health Care index rose 9.05% in July with rotation into the sector gaining momentum  Lumos soared 170% in July after six-year exclusive deal valued at up to US$317 million with PHASE Scientific for distribution of Febri...

ASX surges 1.37pc, smashing through record to close at 8757 points All 11 sectors neon green, up between 2.47pc and 0.46pc Healthcare and resources stocks crank higher, leading gains DJ play it louder It was a raver of a party on the ASX...

ASX crescendos, adding 0.9pc to close at new all-time high of 8639 points Powerful gains across every sector, with all 11 closing higher Financials leads wins, with major banks at the vanguard A fanfare of triumphs The ASX was singing tod...

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am in the east, once trading kicks...

ASX shrugs off tariff pessimism to climb 0.59pc Gains led by gold and banking stocks Major banks join RBA stablecoin project   Gold and Banks lead ASX charge Let’s see – a 50% tariff on copper, up to 200% on pharmaceuticals, and maybe mor...

The ASX 200 Health Care Index fell 1.05% in June and remains the worst performing sector YTD down 6.64% Morgans healthcare analyst Iain Wilkie said June likely saw some tax loss selling before EOFY  Amplia up 300% in June after complete re...

ASX slips back to even, losing just 1.2 points Info tech sector reverses course, retreating from 1.2pc gain to just 0.2pc Gold shines as USD falls; All Ord Gold index adds 1.09pc   Gold shines, tech declines The info tech sector was provi...

ASX lifts 0.33pc on healthcare sector strength CSL adds 2.4pc as UBS marks ASX healthcare sector as best EPS pick Chinese manufacturing data contracts, but shows signs of stirring   Are healthcare bulls returning? The ASX healthcare secto...

Highlights ASX 200 gains at open driven by resource sector momentum Argosy Minerals advances after securing lithium offtake deal Uvre posts strong gold grades amid New Zealand project acquisition Australian equities ma...

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am, once trading kicks off in earn...

UBS reckons healthcare will fare better than any other ASX sector Bell Potter says Monash IVF has fertile recovery prospects Telix wins FDA usage expansion for prostate cancer imaging     Financial giant UBS has declared that enough is e...

ASX surges 1pc as Iran and Israel approach ceasefire Materials and financials lead gains, adding more than 1.8pc each Energy sector drags, shedding 3.89pc as oil slumps   ASX on the rise as missiles keep firing The ASX shot up 1% today, w...

When it comes to medication adherence, humans are strange beasts in that they will go out of their way not to take crucial therapies in the manner intended. In the case of asthma and chronic obstructive pulmonary disease (COPD), ‘puffer’ co...

The S&P/ASX 200 Health Care Index rose 1.59% in May but remains worst performing sector YTD down 5.65% Morgans healthcare analyst Iain Wilkie said US President Donald Trump’s trade and health policies continue to impact sector Lumos up...

The S&P/ASX 200 Health Care Index rose 2.16% in April with the S&P/ASX 200 rallying 3.6% Morgans healthcare analyst Iain Wilkie said April was a marked improvement on recent months Several approvals during April, including for EBR...

Australia’s S&P/ASX 200 rallies 3.62% in April, showing resilience to global geopolitical and economic uncertainty Ten out of 11 sectors post gains in April, led by communications up 6.47% followed by a 6.37% comeback from tech DY6 Met...

Life science companies are turning to federal research & development tax refund advances to stave off capital raisings on unfavourable terms Biotechs undergoing eligible R&D know they will receive a federal R&D rebate, but ther...

Highlights Adherium (ADR) raises $2.6 million through convertible notes Funding supports the expansion of the Hailie® Smartinhaler® platform in the U.S. Company aims to onboard 9,000 active patients by the end of 2025 Adherium (AS...

The S&P/ASX 200 Health Care Index fell 7.66% in February with the S&P/ASX 200 down 3.79% Morgans healthcare analyst Iain Wilkie said several factors caused investor jitters in February including job cuts to US FDA  Pacific Edge was...

ASX drops on tariff fears; BHP, Rio hit Star Entertainment Group sinks amid financial crisis Life360 shines as Endeavour tanks   It was a rough day for the ASX, dropping 1.16% as fears over new US-China tariffs sent Aussie stocks spiralli...

ASX reverses gains, CSL and Brambles weigh IG6, Pilbara, Arafura surge on funding All eyes now on the US CPI report   The ASX had a bumpy ride on Wednesday, down by 0.22% after an afternoon selloff, erasing earlier property stock-led mome...

Highlights Adherium Ltd (ASX:ADR) expected to reach break-even by 2027. Analysts project an impressive 74% annual growth rate to achieve profitability. Strong financial positioning with zero debt on its balance sheet. Adherium Ltd...

The S&P/ASX 200 Health Care Index fell 1.85% in December but rose 7.51% overall in 2024  Mesoblast surged 52% in December after the US FDA approved its cell therapy Ryoncil for treatment of paediatric GvHD Percheron plunged 91% in Dece...

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

ASX up, Xero leads gains Miners hit as iron ore drops, Variscan jumps 50pc Asian stocks down, Bitcoin hits US$93k before retreating   Aussie shares climbed higher on Thursday, powered by a rally in tech companies and the big banks. At the...

ASX 200 drops as gold, iron ore and energy stocks struggle Paladin shares plunge after cutting uranium output forecast Australian business confidence hits two-year high amid easing inflation   The ASX 200 index slipped by 0.13% on Tuesday...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

Aussie shares slip as RBA holds rates steady MinRes rebounds, Domino’s Don Meij quits Investors rethink Trump comeback as Harris leads in Iowa   Aussie shares slipped into the red on Tuesday, falling 0.4% as sentiment remained subdued aft...

  ASX 200 hits record highs fuelled by Wall Street rally Tech and iron ore stocks lead gains Tyro sinks after government proposes new rules on debit surcharge   The ASX 200 index hit record highs on Tuesday after rising by 0.9%, eclipsin...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

ANDHealth says the Covid-19 pandemic triggered far-reaching changes to Australia’s health system and how we manage respiratory illnesses Lumos Diagnostics has developed FebriDx to helps doctors quickly differentiate a viral from bacterial...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

For biotech investors, the news of an approval by the US FDA is a genuinely exciting milestone. The FDA is the ultimate gatekeeper for the US pharmaceutical market, which is by far the world’s largest. Approval from the FDA not only validat...

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

Australian respiratory eHealth company Adherium (ASX:ADR) has announced that AstraZeneca has selected its Hailie Smartinhaler platform for a clinical trial.

ASX in broad rebound; Cettire, Neuren, and Lendlease lead surge Positive sentiment follows Wall Street strength DY6 Metals up 300pc on  Rare Earths find at the Tundulu project in Malawi   Aussie shares rebounded pretty much across the boa...

ASX drops over 1pc as tech, retail, banks fall; energy resists Bond yields surge, impacting goldies Ethereum ETFs approved, await filings   Energy was the only sector showing some sort of resistance on Friday as the ASX was engulfed in a...

Digital health solutions specialist Adherium (ASX: ADR) is celebrating news that global biopharmaceutical giant AstraZeneca has selected its Hailie Smartinhaler platform for a clinical trial. Under the contract, valued at $1.1 million, Astr...

  To register for today's webinar click here. Adherium (ASX:ADR), a leader in respiratory eHealth, remote monitoring and data management solutions, today announced that AstraZeneca has selected its Hailie® Smartinhaler® platform for a clini...

24 May 2024 - A snapshot of the stocks on the move, featuring Adherium (ASX:ADR), Nanoveu (ASX:NVU) and Nimy Resources (ASX:NIM).

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

S&P/ASX 200 fell 2.94% in April as all Australian equity indexes fell except Emerging Companies Utilities and Materials the only ASX sectors in positive territory for April, up 4.77% and 0.61% respectively Rincon Resources  tops the wi...

Asthma affects hundreds of millions of people globally While inhalers are effective, people are not taking them correctly Adherium addresses this problem, as we reached out to CEO Paul Mastoridis   It’s one of the most common chronic dise...

The ASX slumped by over -1pc, as jitters about delayed rate cuts rattled markets Miner BHP confirmed  $60 billion bid for competitor Anglo American Gold stocks climbed, but all 11 sectors closed in the red   The ASX 200 declined sharply b...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...